Article type: Original article

Title: “Genomic and phenotypic characterization of Investigator Global Assessment (IGA) scale based endotypes in atopic dermatitis”

Sandra P Smieszek¹, Bartłomiej Przychodzen¹, Sarah E Welsh¹, Jennifer Brzezynski¹, Alyssa Kaden¹, Michael Mohrman¹, Jingyuan Wang¹, Changfu Xiao¹, Sonja Ständer², Gunther Birznieks¹, Christos Polymeropoulos¹, Mihael H Polymeropoulos¹

¹Vanda Pharmaceuticals, 2200 Pennsylvania NW, Suite 300-E, Washington, DC 20037

²Department of Dermatology, Center for Chronic Pruritus, University Hospital Münster, Germany

Twitter handle: @vandapharma

Corresponding author:

Sandra P. Smieszek
2200 Pennsylvania NW, Suite 300-E
Washington, DC 20037
Email: sandra.smieszek@vandapharma.com

Funding sources: Vanda Pharmaceuticals

Conflicts of Interest: SPS is an employee of Vanda and a stockholder. BPP is an employee of Vanda and a stockholder. SEW is an employee of Vanda and a stockholder. JB is an employee of Vanda and a stockholder. AK is an employee of Vanda and a stockholder. MM is an employee of Vanda and a stockholder. CX is an employee of Vanda and a stockholder. CP is an employee of Vanda and a stockholder. GB is an employee of Vanda and a stockholder. MHP is Chief Executive Officer of Vanda.

IRB approval status: Reviewed and approved by Advarra IRB; Pro00025510

Clinicaltrials.gov listing: NCT03568331

Reprint requests: Sandra Smieszek

Manuscript word count: 2534

Abstract word count: 195

Capsule summary word count: 48

References: 3

Figures: 5

Supplementary **Figures:** 4

Tables: 1

Supplementary tables: 2

41 Attachments: 1

42 **Keywords:** Atopic dermatitis; itch; endotypes; whole genome sequencing; cytokines

43

44 **Abbreviations**

AD	Atopic Dermatitis
EDC	Epidermal Differentiation Complex
EOS	Eosinophils
FLG	Filaggrin
IGA	Investigator's Global Assessment
IL	Interleukin
LOF	Loss-of-Function
NK1R	Neurokinin-1 Receptor
SCORAD	SCORing Atopic Dermatitis
SP	Substance P
vIGA-AD	Validated Investigator Global Assessment for Atopic Dermatitis

45

46

ABSTRACT

Background: Atopic dermatitis (AD) is a heritable and heterogeneous inflammatory chronic skin disorder. Utilizing decision tree/supervised learning of extensive clinical, molecular and genetic data, we aimed to define distinct AD endotypes.

Methods: Deep phenotyping and whole-genome sequencing was performed on samples obtained from participants of EPIONE, a randomized-controlled phase III study in AD patients with severe pruritus comprising mild (23%), moderate (64%) and severe (13%) AD as determined by AD Investigator Global Assessment scale . Three categories of analysis were performed: clinical associations, lab value associations (EOS, IgE, cytokines) and genetic analysis of whole-genome sequencing data

Results: Based on a decision tree, we found that five clinical features from the SCORing Atopic Dermatitis (SCORAD) Index can accurately differentiate between IGA severities. We observe a significant difference between severity and eosinophil counts ($p < 0.001$), IgE ($p < 0.001$) and *Filaggrin (FLG)* LOF frequency (OR 2.3, CI 1.6-3.2, $p < 0.0001$) as well as interleukin pathway genes, specifically IL5RA variants differentiating the groups.

Conclusion: Our results suggest significant differences between severity groups across a number of features appear to constitute distinct endotypes with likely distinct causative factors. Differing underlying pathophysiology's indicate endotype knowledge is critical to help guide therapeutic approaches to AD.

Capsule summary

- AD is a heritable and heterogeneous skin disorder that makes the ‘one size fits all’ therapeutic approach suboptimal for patients with AD.
- We attempted to define AD endotypes based on clinical, molecular, and genetic characteristics. Clinical, CBC, and genetic associations all tend to suggest existence of separate endotypes.

Introduction

Atopic dermatitis (AD) is a complex and heterogeneous, highly heritable, chronic-relapsing, inflammatory skin disorder. AD affects 7.3% of US adults^{1,2}. The genetic background of AD is complex and likely composed of a mixture of rare and common variants. The heritability of AD is estimated to be around 75%². Studies have shown that there are genetic factors specific to AD beyond those for general atopy^{3,4}. AD is manifested by a wide range of symptoms and significantly impacts quality of life. Flares are usually characterized by extreme pruritus of red, rough, flaky and often fissured regions of the skin, that over time thicken². Chronic pruritus, lasting more than 6 weeks, is a key feature associated with AD. The extent of skin lesions and other physical symptoms vary within this patient population and can be diagnosed as mild, moderate, or severe as defined by the Investigator Global Assessment scale for Atopic Dermatitis (vIGA-ADTM). The etiology is likely resultant from an interaction between the genetically determined skin barrier, immune system dysregulation, and the environmental triggers².

One of the main functions of the skin is to act as a barrier between the individual and the environment, preventing water loss and at the same time preventing pathogen and allergen entry⁵. Skin barrier dysfunction is a key clinical feature of AD, as this facilitates penetration of allergens, immunological dysfunction, and consequently an increased risk of developing eczema^{5,6}. The skin barrier dysfunction has, among others, been associated with the etiology of the itch-scratch cycle⁷. In addition, genes encoding skin barrier proteins have been shown to play a role in the heritability of AD^{8,9}. Loss-of-function (LOF) variants resulting in aberrant *FLG* production, constitute the best-known AD gene-association and have been shown to predispose individuals to AD^{10,11}. Individuals harboring *FLG* LOF variants manifest clinical features such as dry and fissured skin. LOF variants in *FLG* are associated with lower levels of

96 natural moisturizing factors in AD¹². Additional genes involved in skin barrier function,
 97 including epidermal differentiation complex (EDC) proteins, are thought to have a potential role
 98 in AD. The EDC encodes proteins critical to the proper development of keratinocytes and normal
 99 formation of the skin barrier¹³. Downregulation of EDC genes has also been implicated in
 100 AD^{14,15,16,17}.

101 Disrupted skin barrier promotes penetration of allergens, immunological dysfunction, and
 102 consequently an increased risk of developing eczema¹⁸. Critical features of the TH2 immune
 103 response include local production of TH2 cytokines activation of eosinophils (EOS) and mast
 104 cells, as well as production of IgE¹⁹. Ultimately T-cell subsets, including Th2/Th22 cells, are
 105 upregulated in AD skin²⁰. Interestingly both lesional and nonlesional AD showed a highly
 106 polyclonal T cell receptor pattern, insinuating the lasting presence of potentially pathogenic
 107 memory T cells beyond clinically inflamed lesions²⁰. Ultimately dysregulation leads to increased
 108 production of neuropeptides such as substance P (SP) released from primary sensory nerves in
 109 the skin²¹. SP binds the neurokinin-1 receptor (NK1R) and MRGPRs²². Elevated SP levels have
 110 been observed in the blood and lesional skin of AD patients, and have been correlated with itch
 111 intensity, as shown in challenge studies and further reiterated in transcriptome analysis^{23, 7}.

112 Elevated SP levels further elicit vasodilation of short duration leading to mast cell degranulation,
 113 nerve growth factor expression in keratinocytes, and neurogenic inflammation associated with
 114 erythema and pruritus²¹. Proof of concept studies have shown increases in itch resulting from
 115 injected SP and expression of NK1R in keratinocytes, as well as reduction in itch resulting from
 116 inhibition of NK1R. Pruritus, perpetuates scratching that further damages the skin barrier⁷.

117 Our work aimed to evaluate the effect of clinical manifestations, molecular levels and genetic
 118 associations and cytokine levels to further understand the architecture and variability of AD as

119 assessed in subjects during baseline visit. We aim to discern whether degree of severity

120 recapitulates individual endotypes in AD.

121

Results

EPIONE, a multi-center, placebo-controlled, double-blind study, enrolled and randomly assigned (1:1) 375 patients aged 18 to 70 with AD. Welsh et al., 2020 (manuscript under review) describes the efficacy and safety results from EPIONE. At baseline, participants presented with a range of disease severities from mild (23%) to moderate (64%), and severe (13%). Severity was defined by Investigator Global Assessment for Atopic Dermatitis (vIGA-ADTM). For analysis, milder AD was defined as IGA scores of 1 (1) or 2 (77) at baseline, while more severe AD was defined as IGA scores of 3 (218) or 4 (33). In addition to deep phenotyping we obtained AD samples for whole genome sequencing (n=765 entire study population, n=332 randomized patients). **Table 1** shows demographic and clinical characteristics of the studied cohort at baseline. **Figure 1** depicts the baseline clinical and lab measurements across IGA groups. We examine each sub-component in depth in the sections that follow.

Clinical Association

We collected extensive clinical information using the SCORAD index including total area involved, intensity, and subjective measurements^{24, 25}. As expected, we observe that mild AD presents with fewer lesions, mild erythema, and minimal induration/papulation or oozing/crusting. In contrast, severe AD presents with a larger number of erythematous lesions associated with significant induration/papulation, oozing/crusting. Importantly, we observed that the interaction between three most informative variables (Edema/Papules, Erythema and Total Area Affected) can classify patients by disease severity. The most severe patients present almost exclusively with highest SCORAD Edema/Papules score (3 on a 0-3 scale) or SCORAD Erythema (3 on a 0-3 scale). Utilizing only those two variables we can accurately identify 35.8% of IGA3/4 with only 2.5% of IGA1/2 falling into that category (**Figure 2A-B**). Remaining 64.2%

of IGA3/4 patients are more difficult to distinguish from IGA1/2. There is a clear separation of the remaining IGA3/4 patients by the SCORAD Total Affected Area (**Figure 2C**).

We performed a series of classification and regression analyses to understand the underlying nature of the severity subgroups utilizing multiple clinical variables at once. We focus our analysis using classification trees. Based on a series of five clinical features from the SCORAD scale, we were able to accurately differentiate between IGA 1/2 versus IGA 3/4. We obtained a robust classification using SCORAD Total Affected Area (%), Edema/Papules, Erythema, Lichenification, and Excoriation. Five-fold cross-validation classification (J48) yields weighted 83.8% precision and 80.1% recall and a large AUC 0.830. **Supplementary Figure 1** displays the actual tree (J48) revealing the cutoffs and splits.

Eosinophils and IgE

Motivated by the hypothesis that atopy is key in the expression of AD, we evaluated the role of counts of eosinophils and levels of IgE and their association with the clinical expression of AD. We evaluated lab values (EOS, IgE, systemic cytokines) that may differentiate milder from more severe AD. We detect a significant association between IGA and EOS levels. We have shown that more severe AD (IGA3/4) is associated with significantly higher counts of eosinophils as compared to milder AD (IGA1/2) (**Figure 1**), an effect that is significant (Mann-Whitney $p < 0.01$). The effect is persistent in an extended screening cohort of 765 samples. Moreover, there is a significant difference between IGA 3 and 4 in the EOS levels ($p < 0.0008$) and 1/2 vs. 4 ($p < 0.0001$). This suggests that systemic eosinophil levels are increasingly correlated across the IGA severity scale. All but 3 cases of the 32 cases above 0.5 are moderate to severe AD subjects

(29/282 of IGA3/4 and only 3/79 IGA1/2). Additionally, we report a significant difference in distribution of patients with elevated serum IgE (**Figure 1D**, ≥ 100 IU/mL, $p < 0.001$).

Genetic landscape of AD endotypes

We performed whole genome sequencing of the entire study population ($n=765$). We investigated the incidence of all *FLG* LOF variants in the genomes of the EPIONE study patients, and compared them with the whole genome sequences of a control population ($n=316$) of healthy volunteers as well as individuals from gnomAD database. More severe AD is associated with a higher prevalence of *FLG* LOF variants ($p < 0.0001$, OR: 2.3, CI: 1.6-3.2). This is significant enrichment as compared to milder ($p=0.99$, OR: 0.89, CI: 0.3-2.0). Milder AD has incidence of LOF *FLG* variants comparable to normal population as defined by gnomAD and an internal set of controls (IGA1/2: 6.4%, Vanda Controls: 6.2%, GnomAD: 8.4%) whereas the moderate to severe subgroup has an elevated frequency of LOF *FLG* variants (IGA3/4: 17.7%). This is contrary to the general observation that AD cases have higher prevalence of *FLG* mutations than the control population, as this effect seems to be specific to IGA3/4 subjects. The variants detected are depicted on **Figure 3** which displays the location of individual LOF variants in both endotypes. We have now showed that the increased frequency can be ascribed to the severe AD subtypes. The results are consistent for EDC gene variants. Furthermore, we detect higher frequency if individuals with two or more *FLG* mutations in the severe group as well as incidence of cases with CNV within the *FLG* gene present in the IGA3/4. The allelic frequency of the two prevalent *FLG* LOF variants, p.R501* and p.S761fs as well as the OR is displayed on panel B of **Figure 3**.

IL5RA gene rare variants differentiate between IGA subgroups

We have performed *in silico* interleukin (IL) screen using gene-centric collapsing analysis on a pathway of IL genes as defined by GO terms, comprised of 96 genes. In a rare variant analysis we obtain a significant result after conservative multiple hypothesis testing in IL5RA as differentiating between the two severity groups. Direction of effect is consistent with a higher EOS levels observed in IGA3/4. Binding of IL-5 to the α -subunit of the IL5Ra promotes the heterodimerization of α and β subunits. As a result, many signal transduction pathways are activated, including JAK/STAT modules, MAPK, PI3K, and NF- κ B. The stimulation of these kinases and TFs drives the expression of key genes responsible for differentiation, survival, degranulation, adhesion, and recruitment of eosinophils. Furthermore through whole genome sequence analysis we have also discovered that polymorphisms in the IL5RA gene are associated with higher count of eosinophils in this population of AD patients. The IL5Ra rare variant rs200005614 associates with significantly higher level of EOS consistent with the effect observed. Previously other variants were found to be associated with EOS such as *IL5RA* c.-5091G>A which was shown to be associated with eosinophil count. *IL5RA* plays an important role in coordinating the release of eosinophil and IgE production against antigens leading to the development of atopy. The association of the IL5RA variants with the blood eosinophil counts and the severe IGA indicates that the IL5RA gene has a role for controlling crucial role in eosinophil responses.

Cytokines

We measured a panel of systemic cytokines collected at baseline. We evaluated which cytokines at baseline are above the normal ranges (as defined by clinical standards²⁶) and show the results on a heatmap of ratios to reference range. This is displayed on **Figure 4** (log2 ratio of cytokine to a maximum value reported in reference range, red being above threshold levels levels). The

211 observed trends are suggestive of elevated levels of Th2 (IL-4, IL-5, and IL-13). Increased IL-5,
 212 as well as IL-4 and IL-23 form a distinct, predominant group of patients (**Figure 4**).
 213 Interestingly, there is a subgroup of patients that also have elevated IL-6, IL-8, and IL-13 (blue
 214 ribbon highlight on **Figure 4**). IL-5 is produced by type 2 T helper cells and mast cells. It
 215 stimulates B cell growth and increases immunoglobulin secretion, and primarily is the key
 216 mediator of eosinophil activation. Its high expression has been previously associated with
 217 chronic AD. It stimulates activated B cell and T cell proliferation, and differentiation of B cells
 218 into plasma cells. IL-4 has been implicated in tissue inflammation and epidermal barrier
 219 dysfunction²⁷. These patients have decreased IFN-gamma and IL-12 levels across all patients,
 220 not limited to patients with elevated Th2. Whereas the main signature pattern (elevated IL-4, IL-
 221 5, and IL-23) is still as abundant in IGAs 1/2 and even 3s, subjects defined as 4 lack a subgroup
 222 of patients with high level of IL-6, IL-8, and IL-13. **Figure 5** displays the cytokine levels in IGA
 223 subgroups. There is a distinct group of patients across all IGA severities that has low systemic
 224 levels of all cytokines. In addition, many more severe outliers have several magnitude higher
 225 levels across the entire cytokine panel as compared to milder cases.

Discussion

Defining AD subtypes has been a debated subject in the field. Definitions analogous to asthma have been previously used based on elevated IgE: with presence ("extrinsic") or absence ("intrinsic") of increased IgE²⁸. Now, endotypes defined by different age groups, ethnicities and according to IgE levels and FLG mutation status are in the scope of discussions⁸. Rare information is available regarding endotypes and different stages of AD in one population. According to epidemiological studies, mild AD is the most common type of AD, affecting approximately 60% of AD cases. The factors underlying severity are not well understood. We present here clinical and genetic evidence supporting the concept of AD in different stages being composed of distinct endotypes. Clinical features suggest milder and severe AD appear to be distinct entities that can be differentiated by five clinical features from the SCORAD index. More severe AD is associated with a higher prevalence of mutation burden in the FLG skin barrier structural protein. These data are consistent with previous investigations, including a study in Denmark on (n=470) patients with AD²⁹, as well as extensive studies of *FLG* gene⁵. We found that more severe AD is associated with significantly higher count of eosinophils as compared to milder AD. Eosinophils are mediators of the inflammatory response and are responsible for recruiting other immune cells in the lesions. As such, it is likely that severe pruritus associated with both mild and severe AD may have different mediators (inflammation, skin barrier disturbance). Based on our findings we hypothesize that the contribution of SP in mild AD, in generating and transmitting the pruritic signal, may be relatively more significant than that seen in severe AD where inflammation dominates. Through whole genome sequence analysis we have also discovered that polymorphisms in the *IL5Ra* gene are associated with higher count of eosinophils in this population of AD patients. The association between

eosinophils and IL5RA has been previously reported in asthmatic patients³⁰. Here we find the association by gene-centric testing between the two severity groups. This is in agreement with a reported association of rs2522411 variant in the IL-5 gene which was significantly associated with extrinsic AD³⁰. When evaluating IL genes we detect IL5RA rare variants further differentiating between severities, with rare IL5RA variants accumulating in the more severe cases.

The described findings lend credence to the existence of endotypes within AD that are manifested clinically and are becoming more understood in terms of underlying mechanisms. These findings may have implications for both diagnosis and treatment course of the disorder. As seen in (Welsh et al. 2020, unpublished) a robust anti-pruritic effect was observed in only the IGA1/2 population while the difference from placebo was not significant in the more severe IGA population. Endotype analyses define the underlying clinical and genetic factors of mild versus more severe AD, and would indicate that the immune response and skin barrier dysfunction tends to be increased in more severe AD. This may mean treating such patients may require more immunosuppressive/immunomodulating therapies. In contrast, mild patients without such underlying factors may be better served with direct targeted therapies such as an anti-pruritic agent addressing the severe itch they may still experience despite their lesions being almost clear or mild. Further attempts to define AD endotypes should be made to define the optimal therapeutic approach, moving towards precision medicine-based treatment of AD based on clinical, molecular, and genetic characteristics.

269 **Acknowledgements**

270 We are grateful to all the study participants and all whom made the study possible

271 **Figure legend**

272 **Figure 1.** Atopic dermatitis endotypes

273 **Figure 2.** Differences between mild and moderate to severe subtypes in terms of clinical feature
274 space

275 **Figure 3.** FLG LOF variants across IGA endotypes

276 **Figure 4.** Cytokine panel at baseline (ratio to reference range)

277 **Figure 5.** Individual cytokine scatter plots

Table legend

Table 1. Baseline demographic and clinical characteristics

	Overall
	N=341
Age, mean (SD)	41.6 (15.3)
Male, n (%)	118 (34.6)
Ethnic origin, n (%)	
White	228 (66.9)
Black	83 (24.3)
Asian	19 (5.6)
Other	11 (3.2)
BMI (kg/m ²)	28.2 (5.2)
WI-NRS	8.2 (1.3)
BSA	14.21 (17.2)
SCORAD	50.5 (14.5)
EASI	10.54 (10.4)
vIGA-AD, n (%)	
Almost Clear (1)	2 (0.6)
Mild (2)	77 (22.6)
Moderate (3)	218 (63.9)
Severe (4)	44 (12.9)
Eosinophil Count (10 ⁹ /L)	0.25 (0.2)
FLG LOF	51 (15.4)
IgE, n (% of ≥100 kU/L)	167 (49.0)

References

1. Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population. *J Invest Dermatol*. 2019;139(3):583-590. doi:10.1016/j.jid.2018.08.028
2. Stein SL, Cifu AS. Management of Atopic Dermatitis. *JAMA*. 2016;315(14):1510-1511. doi:10.1001/JAMA.2016.1459
3. Dold S, Wjst M, von Mutius E, Reitmeir P, Stiepel E. Genetic risk for asthma, allergic rhinitis, and atopic dermatitis. *Arch Dis Child*. 1992;67(8):1018-1022. doi:10.1136/ad.67.8.1018
4. Barnes KC. An update on the genetics of atopic dermatitis: scratching the surface in 2009. *J Allergy Clin Immunol*. 2010;125(1):16-29.e1-11; quiz 30-1. doi:10.1016/j.jaci.2009.11.008
5. Chen H, Common JEA, Haines RL, et al. Wide spectrum of filaggrin-null mutations in atopic dermatitis highlights differences between Singaporean Chinese and European populations. *Br J Dermatol*. 2011;165(1):106-114. doi:10.1111/j.1365-2133.2011.10331.x
6. Gao P-S, Rafaels NM, Hand T, et al. Filaggrin mutations that confer risk of atopic dermatitis confer greater risk for eczema herpeticum. *J Allergy Clin Immunol*. 2009;124(3):507-513, 513.e1-7. doi:10.1016/j.jaci.2009.07.034
7. Nattkemper LA, Tey HL, Valdes-Rodriguez R, et al. The Genetics of Chronic Itch: Gene Expression in the Skin of Patients with Atopic Dermatitis and Psoriasis with Severe Itch. *J Invest Dermatol*. 2018;138(6):1311-1317. doi:10.1016/j.jid.2017.12.029
8. Czarnecki T, Krueger JG, Guttman-Yassky E. Skin Barrier and Immune Dysregulation in Atopic Dermatitis: An Evolving Story with Important Clinical Implications. *J Allergy Clin Immunol Pract*. 2014;2(4):371-379. doi:10.1016/J.JAIP.2014.03.006
9. Bin L, Leung DYM. Genetic and epigenetic studies of atopic dermatitis. *Allergy, Asthma Clin Immunol*. 2016;12(1):52. doi:10.1186/s13223-016-0158-5
10. Margolis DJ, Apter AJ, Gupta J, et al. The persistence of atopic dermatitis and filaggrin (FLG) mutations in a US longitudinal cohort. *J Allergy Clin Immunol*. 2012;130(4):912-917. doi:10.1016/j.jaci.2012.07.008
11. Smieszek SP, Welsh S, Xiao C, et al. Correlation of age-of-onset of Atopic Dermatitis with Filaggrin loss-of-function variant status. *Sci Rep*. 2020;10(1):2721. doi:10.1038/s41598-020-59627-7
12. Engebretsen KA, Bandier J, Kezic S, et al. Concentration of filaggrin monomers, its metabolites and corneocyte surface texture in individuals with a history of atopic dermatitis and controls. *J Eur Acad Dermatology Venereol*. 2018;32(5):796-804. doi:10.1111/jdv.14801
13. Mischke D, Korge BP, Marenholz I, Volz A, Ziegler A. *Genes Encoding Structural Proteins of Epidermal Cornification and S100 Calcium-Binding Proteins Form a Gene Complex ('Epidermal Differentiation Complex') on Human Chromosome Lq21*. Vol 106.; 1996. doi:10.1111/1523-1747.ep12338501
14. Kypriotou M, Huber M, Hohl D. The human epidermal differentiation complex: cornified envelope precursors, S100 proteins and the 'fused genes' family. *Exp Dermatol*. 2012;21(9):643-649. doi:10.1111/j.1600-0625.2012.01472.x
15. Guttman-Yassky E, Suárez-Fariñas M, Chiricozzi A, et al. Broad defects in epidermal

- cornification in atopic dermatitis identified through genomic analysis. *J Allergy Clin Immunol.* 2009;124(6):1235-1244.e58. doi:10.1016/j.jaci.2009.09.031
16. Jensen J-M, Fölster-Holst R, Baranowsky A, et al. Impaired Sphingomyelinase Activity and Epidermal Differentiation in Atopic Dermatitis. *J Invest Dermatol.* 2004;122(6):1423-1431. doi:10.1111/j.0022-202X.2004.22621.x
17. Sugiura H, Ebise H, Tazawa T, et al. Large-scale DNA microarray analysis of atopic skin lesions shows overexpression of an epidermal differentiation gene cluster in the alternative pathway and lack of protective gene expression in the cornified envelope. *Br J Dermatol.* 2005;152(1):146-149. doi:10.1111/j.1365-2133.2005.06352.x
18. Sandilands A, Terron-Kwiatkowski A, Hull PR, et al. Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. *Nat Genet.* 2007;39(5):650-654. doi:10.1038/ng2020
19. McAleer MA, Irvine AD. The multifunctional role of filaggrin in allergic skin disease. *J Allergy Clin Immunol.* 2013;131(2):280-291. doi:10.1016/j.jaci.2012.12.668
20. Brunner PM, Emerson RO, Tipton C, et al. Nonlesional atopic dermatitis skin shares similar T-cell clones with lesional tissues. *Allergy.* 2017;72(12):2017-2025. doi:10.1111/all.13223
21. Ständer S, Yosipovitch G. Substance P and neurokinin 1 receptor are new targets for the treatment of chronic pruritus. *Br J Dermatol.* 2019;181(5):932-938. doi:10.1111/bjd.18025
22. Azimi E, Reddy VB, Shade K-TC, et al. Dual action of neurokinin-1 antagonists on Mas-related GPCRs. *JCI Insight.* 2016;1(16):e89362. doi:10.1172/jci.insight.89362
23. Teresiak-Mikołajczak E, Czarnecka-Operacz M, Jenerowicz D, Silny W. Neurogenic markers of the inflammatory process in atopic dermatitis: relation to the severity and pruritus. *Adv Dermatology Allergol.* 2013;5(5):286-292. doi:10.5114/pdia.2013.38357
24. Schmitt J, Spuls P, Boers M, et al. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. *Allergy.* 2012;67(9):1111-1117. doi:10.1111/j.1398-9995.2012.02874.x
25. Severity Scoring of Atopic Dermatitis: The SCORAD Index. *Dermatology.* 1993;186(1):23-31. doi:10.1159/000247298
26. Kleiner G, Marcuzzi A, Zanin V, Monasta L, Zauli G. Cytokine levels in the serum of healthy subjects. *Mediators Inflamm.* 2013;2013. doi:10.1155/2013/434010
27. Hänel KH, Cornelissen C, Lüscher B, Baron JM. Cytokines and the skin barrier. *Int J Mol Sci.* 2013;14(4):6720-6745. doi:10.3390/ijms14046720
28. Karimkhani C, Silverberg JI, Dellavalle RP. Defining intrinsic vs. extrinsic atopic dermatitis. *Dermatol Online J.* 2015;21(6). <http://www.ncbi.nlm.nih.gov/pubmed/26158358>. Accessed March 11, 2020.
29. Holm JG, Agner T, Clausen M-L, Thomsen SF. Determinants of disease severity among patients with atopic dermatitis: association with components of the atopic march. *Arch Dermatol Res.* 2019;311(3):173-182. doi:10.1007/s00403-019-01895-z
30. Namkung J-H, Lee J-E, Kim E, et al. IL-5 and IL-5 receptor alpha polymorphisms are associated with atopic dermatitis in Koreans. *Allergy.* 2007;62(8):934-942. doi:10.1111/j.1398-9995.2007.01445.x

A **SCORAD - total score**

B **BSA**

C **EOS by IGA**

D **IgE**

A

B

C

Erythema

Edema/Papules

D

FLG LOF's

IGA1+2

IGA3

IGA4

GMCSF

IFN γ

IL12p70

IL1 β

IL4

IL5

IL6

IL8

IL13

IL23

TNF α

IL17A